Text-message Reminders to Increase Rates of Postpartum Diabetes Screening in Women With Gestational Diabetes
Purpose: The purpose of this study is to see whether a text-message reminder system will increase the number of women who complete their diabetes screening after delivery.
Study Design: Prospective randomized control trial
Hypothesis: Gestational diabetics will be significantly more likely to follow up with their postpartum screening for diabetes if they receive text-message reminders to set up their lab appointment compared to those who receive usual care.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Screening
|Official Title:||Text-message Reminders to Increase Rates of Postpartum Diabetes Screening in Women With Gestational Diabetes|
- Percentage of patients that receive the 2-hour 75-g oral glucose tolerance test [ Time Frame: Within six months of their delivery date ] [ Designated as safety issue: No ]
- Percentage of patients that receive any type of postpartum diabetes screening [ Time Frame: Within six months of their delivery date ] [ Designated as safety issue: No ]This can include any of the multiple forms of diabetes screening tests including: 75-g oral glucose tolerance test, Hemoglobin A1c, fasting plasma glucose test or others.
|Study Start Date:||January 2014|
|Estimated Study Completion Date:||May 2016|
|Estimated Primary Completion Date:||May 2016 (Final data collection date for primary outcome measure)|
Experimental: Intervention Group
Women in the intervention group will receive a test text-message reminder at the time of enrollment. They will then receive a text-reminder to schedule their oral glucose tolerance test at 6 weeks postpartum, with further reminders at 3 months and 6 months if they have not completed their testing.
|Behavioral: Text-message reminder|
No Intervention: Control group
This arm will only receive the test text-message reminder at the time of enrollment. Otherwise they will receive usual postpartum care.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02013557
|Contact: Elisabeth Sappenfield, MD||(850) email@example.com|
|Contact: Carolyn Young, MSN, ARNP||(813) 259-8685||ObGynClinicalResearch@health.usf.edu|
|United States, Florida|
|Tampa General Hospital||Recruiting|
|Tampa, Florida, United States, 33606|
|Sub-Investigator: Angela Gonzalez, MD|
|Sub-Investigator: Judette Louis, MD|
|Sub-Investigator: Elisabeth Sappenfield, MD|
|Sub-Investigator: Branko Miladinovic, PhD|
|Sub-Investigator: Melissa Cardenas|
|Principal Investigator:||Judette Louis, MD||University of South Florida Department of Obstetrics and Gynecology|
|Study Chair:||Angela Gonzalez, MD||University of South Florida Department of Obstetrics and Gynecology|